TY - JOUR
T1 - Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies
AU - Hu, Xiaochen
AU - Teunissen, Charlotte E.
AU - Spottke, Annika
AU - Heneka, Michael T.
AU - Düzel, Emrah
AU - Peters, Oliver
AU - Li, Siyao
AU - Priller, Josef
AU - Buerger, Katharina
AU - Teipel, Stefan
AU - Laske, Christoph
AU - Verfaillie, Sander C.J.
AU - Barkhof, Frederik
AU - Coll-Padrós, Nina
AU - Rami, Lorena
AU - Molinuevo, Jose Luis
AU - van der Flier, Wiesje M.
AU - Jessen, Frank
N1 - Publisher Copyright:
© 2018 the Alzheimer's Association
PY - 2019/2
Y1 - 2019/2
N2 - Introduction: Previous studies showed associations of brain volume differences and biomarker evidence for Alzheimer's disease (AD) in subjective cognitive decline (SCD). The consistency of this finding across SCD studies has not been investigated. Methods: We studied gray matter volume differences between SCD subjects with and without cerebrospinal fluid biomarker evidence for AD across three European memory clinic samples (German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia study, Amsterdam, Barcelona). Analysis of covariance models with samples and cerebrospinal fluid biomarkers as between-subject factors were calculated. Results: A significant main effect for AD biomarker (Aβ 42 − > Aβ 42 +) in the left medial temporal lobe (MTL) was found, with the absence of main effects for sample or interaction effects between AD biomarker and sample. This indicates consistent lower left MTL volume across three samples in SCD subjects with abnormal Aβ 42 levels. Discussion: Our results support the model that in the presence of AD pathology, SCD corresponds to the late preclinical stage (stage 2 of AD) with smaller MTL volumes.
AB - Introduction: Previous studies showed associations of brain volume differences and biomarker evidence for Alzheimer's disease (AD) in subjective cognitive decline (SCD). The consistency of this finding across SCD studies has not been investigated. Methods: We studied gray matter volume differences between SCD subjects with and without cerebrospinal fluid biomarker evidence for AD across three European memory clinic samples (German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia study, Amsterdam, Barcelona). Analysis of covariance models with samples and cerebrospinal fluid biomarkers as between-subject factors were calculated. Results: A significant main effect for AD biomarker (Aβ 42 − > Aβ 42 +) in the left medial temporal lobe (MTL) was found, with the absence of main effects for sample or interaction effects between AD biomarker and sample. This indicates consistent lower left MTL volume across three samples in SCD subjects with abnormal Aβ 42 levels. Discussion: Our results support the model that in the presence of AD pathology, SCD corresponds to the late preclinical stage (stage 2 of AD) with smaller MTL volumes.
KW - AD biomarkers
KW - Alzheimer's disease
KW - Medial temporal lobe
KW - Subjective cognitive decline
UR - http://www.scopus.com/inward/record.url?scp=85056722601&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2018.09.002
DO - 10.1016/j.jalz.2018.09.002
M3 - Article
C2 - 30321506
AN - SCOPUS:85056722601
SN - 1552-5260
VL - 15
SP - 185
EP - 193
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 2
ER -
